Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alkermes (ALKS) EBT (2016 - 2025)

Alkermes (ALKS) has disclosed EBT for 16 consecutive years, with $60.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 64.46% to $60.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $291.4 million, a 34.32% decrease, with the full-year FY2025 number at $291.4 million, down 34.32% from a year prior.
  • EBT was $60.4 million for Q4 2025 at Alkermes, down from $100.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $281.8 million in Q2 2023 to a low of -$67.4 million in Q3 2022.
  • A 5-year average of $66.9 million and a median of $76.5 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: crashed 1310.54% in 2021, then skyrocketed 947.61% in 2023.
  • Alkermes' EBT stood at $127.3 million in 2021, then dropped by 10.04% to $114.5 million in 2022, then soared by 59.2% to $182.3 million in 2023, then fell by 6.79% to $169.9 million in 2024, then tumbled by 64.46% to $60.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALKS's EBT are $60.4 million (Q4 2025), $100.7 million (Q3 2025), and $104.8 million (Q2 2025).